Antiproliferative Properties of Sphingosine 1-Phosphate in Human Hepatic Myofibroblasts
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Proliferation of hepatic myofibroblasts (hMF) is central for the development of fibrosis during liver injury, and factors that may limit their growth are potential antifibrotic agents. Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid with growth-regulating properties, either via Edg receptors or through intracellular actions. In this study, we examined the effects of S1P on the proliferation of human hMF. Human hMF expressed mRNAs for the S1P receptors Edg1, Edg3, and Edg5. These receptors were functional at nanomolar concentrations and coupled to pertussis toxin-sensitive and -insensitive G proteins, as demonstrated in guanosine 5'-3-O-(thio)triphosphate binding assays. S1P potently inhibited hMF growth (IC(50) = 1 microm), in a pertussis toxin-insensitive manner. Analysis of the mechanisms involved in growth inhibition revealed that S1P rapidly increased prostaglandin E(2) production and in turn cAMP, two growth inhibitory messengers for hMF; C(2)-ceramide and sphingosine, which inhibited hMF proliferation, did not affect cAMP levels. Production of cAMP by S1P was abolished by NS-398, a selective inhibitor of COX-2. Also, S1P potently induced COX-2 protein expression. Blocking COX-2 by NS-398 blunted the antiproliferative effect of S1P. We conclude that S1P inhibits proliferation of hMF, probably via an intracellular mechanism, through early COX-2-dependent release of prostaglandin E(2) and cAMP, and delayed COX-2 induction. Our results shed light on a novel role for S1P as a growth inhibitory mediator and point out its potential involvement in the negative regulation of liver fibrogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Win, K. M., Charlotte, F., Mallat, A., Cherqui, D., Martin, N., Mavier, P., Preaux, A.-M., Dhumeau, D., & Rosenbaum, J. (1993) · Hepatology · doi:10.1002/hep.1840180121 · Cited by 102
Self-citation
Cited by
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis
Teixeira-Clerc, F., Julien, B., Grenard, P., Van Nhieu, J. T., Deveaux, V., Li, L., Serriere-Lanneau, V., Ledent, C., Mallat, A., & Lotersztajn, S. (2006) · Nature Medicine · doi:10.1038/nm1421 · Cited by 528
Self-citationAntifibrogenic role of the cannabinoid receptor CB2 in the liver
Julien, B., Grenard, P., Teixeira-Clerc, F., Van Nhieu, J. T., Li, L., Karsak, M., Zimmer, A., Mallat, A., & Lotersztajn, S. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.12.050 · Cited by 470
Self-citationHepatic fibrosis: molecular mechanisms and drug targets
Lotersztajn, S., Julien, B., Teixeira-Clerc, F., Grenard, P., & Mallat, A. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095906 · Cited by 325
Self-citationPettus, B. J., Bielawski, J., Porcelli, A. M., Reames, D. L., Johnson, K. R., Morrow, J., Chalfant, C. E., Obeid, L. M., & Hannun, Y. A. (2003) · The FASEB Journal · doi:10.1096/fj.02-1038com · Cited by 320
Targeting dexamethasone to Kupffer cells: Effects on liver inflammation and fibrosis in rats
Melgert, B. N., Olinga, P., Van Der Laan, J. M. S., Weert, B., Cho, J., Schuppan, D., Groothuis, G. M. M., Meijer, D. K. F., & Poelstra, K. (2001) · Hepatology · doi:10.1053/jhep.2001.27805 · Cited by 115
Metadata
- Authors
- Davaille, J., Gallois, C., Habib, A., Li, L., Mallat, A., Tao, J., Levade, T., & Lotersztajn, S.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2000-11
- Volume
- 275
- Issue
- 44
- Pages
- 34628-34633
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2084143813
- Cited by
- 118
- References
- 1
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.